Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 5/20 | 0.36 |
| ▸ | PPARD | Q03181 | 4/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7763494 | 0.85 | ELANE (0.35) | TRPV1ELANE | |
| SCHEMBL9581834 | 0.84 | MAPT (0.44) | CA1CA2CA9TRPV1ELANE | |
| SCHEMBL8803204 | 0.84 | ELANE (0.42) | TRPV1ELANEKIF11 | |
| SCHEMBL9752867 | 0.79 | L3MBTL1 (0.42) | PPARAPPARGMAOB | |
| SCHEMBL9196159 | 0.78 | ACHE (0.41) | CA1CA2CA9ELANEPPARA | |
| SCHEMBL2008822 | 0.78 | ELANE (0.56) | CA1CA2CA9PYCR1ELANE | |
| SCHEMBL11887280 | 0.77 | CA1 (0.45) | CA1CA2CA9TRPV1PPARA | |
| SCHEMBL19477800 | 0.77 | CA1 (0.45) | CA1CA2CA9TRPV1PPARA | |
| SCHEMBL7766937 | 0.77 | ELANE (0.34) | ELANEPPARAPPARG | |
| SCHEMBL9741208 | 0.77 | PTPRZ1 (0.45) | TRPV1ELANEKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3126361-B1 | CHROMENE AND 1,1A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3126361-B1 | CHROMENE AND 1,1A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-11-06 | — | — | EP | disclosed |
| US-9718817-B2 | Aryl and heteroaryl ether compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| US-9718817-B2 | Aryl and heteroaryl ether compounds as ROR gamma modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-08-01 | — | — | US | disclosed |
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PFIZER (US) | 2017-06-15 | — | — | US | disclosed |
| EP-3131880-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-3126361-A1 | CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2017-02-08 | — | — | EP | disclosed |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150957-A1 | CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015150957-A1 | CHROMENE AND 1,1 A,2,7B-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | PFIZER (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | PFIZER (US) | 2015-10-01 | — | — | US | disclosed |
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | PFIZER (US) | 2015-10-01 | — | — | US | disclosed |
| EP-1109801-A1 | SUBSTITUTED DIHYDROBENZOPYRANS USEFUL AS ANTIARRHYTHMIC AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000014084-A1 | SUBSTITUTED DIHYDROBENZOPYRANS USEFUL AS ANTIARRHYTHMIC AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-03-16 | — | — | WO | disclosed |
| US-5118694-A | Hypotensive agents; treatment for cardiovascular and muscular disorders | HOFFMANN-LA ROCHE INC. (US) | 1992-06-02 | — | — | US | disclosed |
| WO-1991009031-A1 | TRIFLUOROMETHYL SUBSTITUTED COMPOUNDS AND A PHARMACEUTICAL COMPOSITION | BEECHAM GROUP PLC (GB) | 1991-06-27 | — | — | WO | disclosed |
| US-4971982-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS, SMOOTH MUSCLE DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1990-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274721-A1 | NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES | CYP4B1, CTRB1, CTRB2 | CA1 3864/4885CA2 2908/4885CA9 4127/4885 |
| US-20170022195-A1 | ARYL AND HETEROARYL ETHER COMPOUNDS AS ROR GAMMA MODULATORS | RORB, RORA, RORC | CA1 3974/4885CA2 3679/4885CA9 3870/4885 |
| US-20170166566-A1 | SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PRNP, MAOB | CA1 4067/4885CA2 4202/4885CA9 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.